Affimed NV
AFMD0.181USD
-0.098-34.95%
Market hours （ET）Quotes delayed by 15 min
2.98MMarket Cap
LossP/E TTM
More Details of Affimed NV Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Info
Ticker SymbolAFMD
Company nameAffimed NV
IPO dateSep 12, 2014
CEOMr. Shawn M. Leland
Number of employees76
Security typeOrdinary Share
Fiscal year-endSep 12
AddressIm Neuenheimer Feld 582
CityHEIDELBERG
Stock exchangeBerne Stock Exchange
CountryGermany
Postal code69120
Phone49621560030
Websitehttps://www.affimed.com/
Ticker SymbolAFMD
IPO dateSep 12, 2014
CEOMr. Shawn M. Leland
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Revenue Breakdown
Currency: EURUpdated: Sun, Jul 6
Currency: EURUpdated: Sun, Jul 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
By RegionEUR
Name
Revenue
Proportion
United States
155.00K
100.00%
Germany
0.00
0.00%
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Shareholders
Shareholders
Proportion
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Shareholder Types
Shareholders
Proportion
Venture Capital
8.49%
Hedge Fund
7.52%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
1.57%
Investment Advisor
1.14%
Research Firm
0.79%
Other
74.48%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
144
3.89M
25.52%
-2.82M
2025Q1
194
5.44M
35.72%
-1.40M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Mar 31, 2025
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Mar 31, 2025
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Mar 31, 2025
Intellectus Partners, LLC
126.41K
0.83%
--
--
Mar 31, 2025
Marshall Wace LLP
111.64K
0.73%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Date
Type
Ratio
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
